Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the "ABCNR" drugs in multiple sclerosis

Semin Neurol. 2002 Mar;22(1):17-25. doi: 10.1055/s-2002-33045.

Abstract

With the development of multiple options for immunotherapy in multiple sclerosis, the clinician is faced with the challenge of keeping pace with the literature, acquiring familiarity with the various treatment options and opinions, and then offering the patients the most current and appropriate management. Given the inherent nature of a multifocal and unpredictable disease such as multiple sclerosis, along with the availability of multiple treatment options, it behooves the clinician to develop an evidence-based rationale for how to best manage patients. This article reflects the common questions that arise from referring neurologists regarding my personal approach to the management of patients with multiple sclerosis.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Algorithms
  • Case Management
  • Drug Evaluation
  • Evidence-Based Medicine*
  • Glatiramer Acetate
  • Humans
  • Immunotherapy
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon-beta / adverse effects
  • Interferon-beta / therapeutic use
  • Magnetic Resonance Imaging
  • Mitoxantrone / adverse effects
  • Mitoxantrone / therapeutic use
  • Multiple Sclerosis / classification
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / pathology
  • Peptides / adverse effects
  • Peptides / therapeutic use
  • Prognosis
  • Remission Induction
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Peptides
  • Interferon beta-1b
  • Glatiramer Acetate
  • Interferon-beta
  • Mitoxantrone
  • Interferon beta-1a